title: Dasatinib-induced nephrotic syndrome.
authors.affiliation: a Department of Hematology and Oncology and.
authors.forename: Taichi
authors.initials: T
authors.lastname: Hirano
authors.affiliation: b Department of Nephrology , Kumamoto City Hospital , Higashi-ward, Kumamoto , Japan.
authors.forename: Miyuki
authors.initials: M
authors.lastname: Hashimoto
authors.affiliation: b Department of Nephrology , Kumamoto City Hospital , Higashi-ward, Kumamoto , Japan.
authors.forename: Yu
authors.initials: Y
authors.lastname: Korogi
authors.affiliation: a Department of Hematology and Oncology and.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Tsuji
authors.affiliation: b Department of Nephrology , Kumamoto City Hospital , Higashi-ward, Kumamoto , Japan.
authors.forename: Kei
authors.initials: K
authors.lastname: Miyanaka
authors.affiliation: a Department of Hematology and Oncology and.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yamasaki
authors.affiliation: a Department of Hematology and Oncology and.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tsuda
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069439:Dasatinib / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000175:diagnosis* / Q000209:etiology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000069439:Dasatinib